Dr Burns continued: “Positive data from this clinical study, combined with promising data from the
current ACCENT trial - where narmafotinib is combined with gemcitabine and Abraxane® - will position
narmafotinib as the preferred drug to combine with the two main chemotherapy regimes used for the
treatment of pancreatic cancer across the globe.”
No comments !!!
Ann: Type D Meeting Outcome With US Food And Drug Administration, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $67.89M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 21.0¢ | 17.0¢ | $2.549M | 13.34M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 73164 | 4 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATX (ASX) Chart |